Bilal Arif
Chief Tech/Sci/R&D Officer presso SAREPTA THERAPEUTICS, INC.
Patrimonio netto: 3 M $ in data 31/03/2024
Profilo
Bilal Arif is currently the Chief Technical Operations Officer & Executive VP at Sarepta Therapeutics, Inc. Previously, he worked as the Vice President-Technical Operations at Momenta Pharmaceuticals, Inc. from 2017 to 2019.
Mr. Arif completed his undergraduate degree at McGill University, his graduate degree at Tufts University, and his MBA at Instituto de Empresa SL.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 08/03/2024 | 25 222 ( 0.03% ) | 3 M $ | 31/03/2024 |
Posizioni attive di Bilal Arif
| Società | Posizione | Inizio |
|---|---|---|
| SAREPTA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 31/12/2022 |
Precedenti posizioni note di Bilal Arif
| Società | Posizione | Fine |
|---|---|---|
| MOMENTA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 02/01/2019 |
Formazione di Bilal Arif
| McGill University | Undergraduate Degree |
| Tufts University | Graduate Degree |
| Instituto de Empresa SL | Masters Business Admin |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Bilal Arif
